GTC Biotherapeutics and LEO Pharma to develop and market ATryn

By Angela McDaniels

GTC Biotherapeutics Inc. and LEO Pharma AS said they have entered into a collaboration agreement to develop and market ATryn in Europe, the Middle East and Canada.

ATryn is GTC's recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties.

According to the agreement:

* GTC will be responsible for production of ATryn and will receive a transfer price for all product used by LEO.

* GTC will receive a royalty on net sales and milestone payments of up to $73 million for meeting regulatory, clinical and sales goals.

* LEO will be responsible for sales and marketing of ATryn in all indications for the agreed territories and clinical development for acquired antithrombin deficiency indications.

* GTC retains all rights to ATryn in all other territories and will continue to be responsible for obtaining approval of ATryn for the hereditary deficiency indication in Europe.

GTC Biotherapeutics is based in Framingham, Mass. and develops therapeutic proteins.

LEO Pharma is based in Ballerup, Denmark, and develops topical dermatology products and parenteral treatments for thromboembolic disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.